1. Home
  2. TSHA vs CHCO Comparison

TSHA vs CHCO Comparison

Compare TSHA & CHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$6.02

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo City Holding Company

CHCO

City Holding Company

HOLD

Current Price

$144.26

Market Cap

2.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSHA
CHCO
Founded
2019
1957
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
2.1B
IPO Year
2020
1995

Fundamental Metrics

Financial Performance
Metric
TSHA
CHCO
Price
$6.02
$144.26
Analyst Decision
Strong Buy
Hold
Analyst Count
8
2
Target Price
$11.63
$132.50
AVG Volume (30 Days)
2.6M
94.2K
Earning Date
05-06-2026
04-23-2026
Dividend Yield
N/A
2.87%
EPS Growth
5.56
13.18
EPS
N/A
4.55
Revenue
$9,773,000.00
N/A
Revenue This Year
N/A
$5.16
Revenue Next Year
$1,152.42
$3.12
P/E Ratio
N/A
$31.65
Revenue Growth
17.28
N/A
52 Week Low
$2.72
$113.21
52 Week High
$7.30
$148.99

Technical Indicators

Market Signals
Indicator
TSHA
CHCO
Relative Strength Index (RSI) 48.49 56.75
Support Level $5.28 $143.67
Resistance Level $6.88 $148.28
Average True Range (ATR) 0.34 2.12
MACD -0.01 -0.73
Stochastic Oscillator 31.82 37.86

Price Performance

Historical Comparison
TSHA
CHCO

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

About CHCO City Holding Company

City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.

Share on Social Networks: